News
PAVM
0.3190
-0.31%
-0.0010
Weekly Report: what happened at PAVM last week (0911-0915)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 09/12 17:31
Weekly Report: what happened at PAVM last week (0904-0908)?
Weekly Report · 09/11 11:21
Weekly Report: what happened at PAVM last week (0828-0901)?
Weekly Report · 09/05 03:29
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 09/04 21:31
Here's Why PAVmed Inc. (PAVM) Is a Great 'Buy the Bottom' Stock Now
NASDAQ · 08/30 13:55
Weekly Report: what happened at PAVM last week (0821-0825)?
Weekly Report · 08/28 11:28
Lucid Diagnostics Executes First Direct Employer Contract To Provide Ancira Auto Group EsoGuard Esophageal Precancer Testing As An Employee Benefit
Benzinga · 08/24 13:06
Cantor Fitzgerald Reiterates PAVmed (PAVM) Neutral Recommendation
NASDAQ · 08/19 00:45
Cantor Fitzgerald Reiterates Neutral on PAVmed, Maintains $1.4 Price Target
Benzinga · 08/18 14:46
PAVmed (PAVM) Receives a Buy from Maxim Group
TipRanks · 08/18 11:45
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 08/16 21:32
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 08/16 17:31
PAVmed Q2 EPS $(0.09) Beats $(0.19) Estimate, Sales $166.00K Miss $520.00K Estimate
Benzinga · 08/16 04:21
More
Webull provides a variety of real-time PAVM stock news. You can receive the latest news about Pavmed through multiple platforms. This information may help you make smarter investment decisions.
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.